Clinical Trial Update: Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating gefitinib plus berberine as first-line therapy for EGFR-mutant lung adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Berberine (berberine)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Lung Adenocarcinoma, EGFR Mutation | Phase 2 | Status: UNKNOWN